FATE
Price
$1.12
Change
-$0.00 (-0.00%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
127.82M
27 days until earnings call
MRKR
Price
$1.60
Change
+$0.03 (+1.91%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
17.09M
Interact to see
Advertisement

FATE vs MRKR

Header iconFATE vs MRKR Comparison
Open Charts FATE vs MRKRBanner chart's image
Fate Therapeutics
Price$1.12
Change-$0.00 (-0.00%)
Volume$37.51K
Capitalization127.82M
Marker Therapeutics
Price$1.60
Change+$0.03 (+1.91%)
Volume$1.21K
Capitalization17.09M
FATE vs MRKR Comparison Chart in %
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. MRKR commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and MRKR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (FATE: $1.12 vs. MRKR: $1.57)
Brand notoriety: FATE and MRKR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 139% vs. MRKR: 29%
Market capitalization -- FATE: $127.82M vs. MRKR: $17.09M
FATE [@Biotechnology] is valued at $127.82M. MRKR’s [@Biotechnology] market capitalization is $17.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileMRKR’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • MRKR’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and MRKR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while MRKR’s TA Score has 6 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 7 bearish.
  • MRKR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MRKR is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -3.88% price change this week, while MRKR (@Biotechnology) price change was +5.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

FATE is expected to report earnings on Jul 30, 2025.

MRKR is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($128M) has a higher market cap than MRKR($17.1M). FATE YTD gains are higher at: -32.424 vs. MRKR (-49.518). MRKR has higher annual earnings (EBITDA): -6.13M vs. FATE (-168.28M). FATE has more cash in the bank: 240M vs. MRKR (13.7M). MRKR has less debt than FATE: MRKR (0) vs FATE (83.3M). FATE has higher revenues than MRKR: FATE (13.3M) vs MRKR (6.59M).
FATEMRKRFATE / MRKR
Capitalization128M17.1M749%
EBITDA-168.28M-6.13M2,743%
Gain YTD-32.424-49.51865%
P/E RatioN/AN/A-
Revenue13.3M6.59M202%
Total Cash240M13.7M1,752%
Total Debt83.3M0-
FUNDAMENTALS RATINGS
FATE vs MRKR: Fundamental Ratings
FATE
MRKR
OUTLOOK RATING
1..100
6154
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
6264
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is in the same range as MRKR (22) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's SMR Rating (96) in the Biotechnology industry is in the same range as MRKR (98) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's Price Growth Rating (62) in the Biotechnology industry is in the same range as MRKR (64) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEMRKR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLB12.901.38
+11.98%
Core Laboratories
ELDN3.070.28
+9.86%
Eledon Pharmaceuticals
NTR59.991.47
+2.51%
Nutrien Ltd
AMTD0.990.01
+1.11%
AMTD IDEA Group
XTIA1.73-0.01
-0.57%
XTI Aerospace Inc

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.19%
ALLO - FATE
57%
Loosely correlated
+0.85%
CRBU - FATE
56%
Loosely correlated
+9.20%
CRSP - FATE
56%
Loosely correlated
+6.51%
RXRX - FATE
55%
Loosely correlated
+1.56%
CCCC - FATE
52%
Loosely correlated
+0.66%
More

MRKR and

Correlation & Price change

A.I.dvisor tells us that MRKR and XNCR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRKR and XNCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
+3.97%
XNCR - MRKR
32%
Poorly correlated
+2.85%
RCKT - MRKR
32%
Poorly correlated
+11.20%
MGNX - MRKR
31%
Poorly correlated
+9.52%
EYPT - MRKR
31%
Poorly correlated
+1.15%
LRMR - MRKR
31%
Poorly correlated
+7.99%
More